760937-92-6 Usage
Description
Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was approved in September 2012 in Japan for the treatment of patients with Type 2 diabetes mellitus (T2DM). It is a potent inhibitor of DPP-4, an enzyme that degrades GLP-1, a peptide that stimulates insulin secretion and inhibits glucagon secretion, leading to lower levels of plasma glucose. The discovery of teneligliptin was guided by structure-based design, with a key element being binding of the phenyl group in the S2 pocket, which increases potency for DPP-4 and improves selectivity versus DPP-8 and DPP-9. It has a half-life of 24.2 hours in the human body and is eliminated via excretion.
Uses
Used in Pharmaceutical Industry:
Teneligliptin is used as an antidiabetes agent for the treatment of Type 2 diabetes mellitus (T2DM). It functions as a DPP-4 inhibitor, increasing the levels of GLP-1, which in turn stimulates insulin secretion and inhibits glucagon secretion, resulting in lower plasma glucose levels.
Originator
Mitsubishi Tanabe Pharma (Japan)
Check Digit Verification of cas no
The CAS Registry Mumber 760937-92-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,6,0,9,3 and 7 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 760937-92:
(8*7)+(7*6)+(6*0)+(5*9)+(4*3)+(3*7)+(2*9)+(1*2)=196
196 % 10 = 6
So 760937-92-6 is a valid CAS Registry Number.
760937-92-6Relevant articles and documents
OXALATE SALTS OF TENELIGLIPTIN AND SOLVATES THEREOF, INTERMEDIATES, PROCESS OF PREPARATION
-
Paragraph 00186, (2018/08/26)
The present invention provides oxalate salts of teneligliptin and solvates thereof exhibiting superior physiochemical properties. In particular, crystalline form of teneligliptin 2.5 oxalate 1.0 hydrate and crystalline form of teneligliptin 3.0 oxalate 1.0 hydrate are disclosed. Also provided are methods of preparing the same, and uses thereof.
Process for the preparation of teneligliptin
-
, (2017/01/02)
A process for the preparation of teneligliptin.
CONCOMITANT PHARMACEUTICAL AGENTS AND USE THEREOF
-
Page/Page column 12, (2008/06/13)
A concomitant agent to be used simultaneously or separately, comprising a combination of (a) 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, a salt of the compound with an organic or inorganic and mono- or di-basic acid or a solvate thereof, and (b) at least one kind of active ingredient selected from the group consisting of an active ingredient of a pharmaceutical agent selected from (i) an antidiabetic drug, (ii) a lipid lowering drug, (iii) an antihypertensive drug, (iv) a therapeutic drug for diabetic complications, (v) an antiobesity drug, (vi) an antiplatelet drug and (vii) an anticoagulant, a pharmaceutically acceptable salt thereof and a solvate thereof.